Social Sentiment for AIMT
Bullish vs. Bearish opinions
Weighted Sentiment 0.10
Aimmune Therapeutics Forecast and Stock Analysis
Technical AIMT stock analysis for Thursday May 23, 2019.
|Price to book||USD 4.96|
|Next Earnings Date||2019-08-06|
Aimmune Therapeutics fell by -2.21% in the last day ( Thursday, 23rd May 2019 ) from $20.35 to $19.90 and has now fallen 3 days in a row. During day the stock fluctuated 3.41% from a day low at $19.63 to a day high of $20.30. The price has fallen in 6 of the last 10 days and is down by -2.93% for this period. Volume has increased in the last day by 155 763 shares, but on falling prices. This may be an early warning and the risk will be increased slightly for the next couple of days. In total, 406 345 shares bought and sold for approximately $8.09 million.
- 30 day high of the AIMT stock price was $22.15 and low was $19.25.
- 90 day high was $25.81 and low was $19.25.
- 52 week high for the Aimmune Therapeutics - $36.12 and low - $19.25.
Aimmune Therapeutics lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -18.41% during the next 3 months and, with 90% probability hold a price between $14.43 and $17.27 at the end of this period.
There are few to none technical positive signals at the moment. Aimmune Therapeutics holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $20.29 and $20.82. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Tuesday May 21, 2019, which indicates further falls until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.
Relative Strength Index (RSI)
RSI14 is 52 and the stock is currently not being overbought or oversold
Support & Resistance
Aimmune Therapeutics finds support from accumulated volume at $19.83.
This stock is usually traded at good volume, and with minor daily changes the risk is considered to be low. During the last day, the stock moved $0.67 (3.41%) between high and low. For the last week, the stock has had a daily average volatility of 3.11%.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
3.11 %Average volatility
Very Low Low Medium High Very High
Aimmune Therapeutics holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
|Golden Star Signal|
Get competitive edge
The signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives a very good return. From 8.000 stocks usually only a few will trigger a Golden Star Signal per day!
Get access to Golden Star list now
|AIMT $19.90 ($-0.45 -2.21%)|
AIMT is down $0.45 today, but where's it headed in 2019?
|Zacks Investment Research is releasing its prediction for AIMT based on the 1-3 month system that more than doubles the S&P 500.
This report is free today for StockInvest.us readers.
Click here – the AIMT analysis is free »
From Our Blog
- Trading With Moving Average
- Pivot Points
- Accumulated Volume - Support and Resistance
- Volume - The Indicator You Really Need to Know
- We Give Back!
- Better Buy: Amazon vs. Facebook
- Better Buy: Apple vs. Microsoft
- Relative Strength Index (RSI)
- How to Lose Money When Trading: Part 2
- How to Lose Money When Trading: A Trader is Born
- Our 2017 Christmas Donation
- The Golden Star
- Announcing Partnership With CityFALCON
- Why correct moving average matters
- NASDAQ down -4.17%. Our portfolio is up +8.56%
- New Feature Added: Golden Star Signal
- Pick a Winner With StockInvest.us